Berns Svetlana A, Isakova Julia A, Pekhtereva Polina I
Federal State Institution National Medical Research Center for therapy and Preventive Medicine of the Ministry of Healthcare of the Russian Federation,
SPP "Pharmaclon" Ltd., Moscow, Russia,
ADMET DMPK. 2022 Feb 14;10(1):63-73. doi: 10.5599/admet.1078. eCollection 2022.
Tuberculosis is one of the critical health problems worldwide. The search for ways to improve the results of tuberculosis treatment and overcome drug resistance lies in understanding the pathogenesis of the development of the infectious process. The interferon system, particularly the role of interferon-gamma, has been identified as the main link in the immune response in tuberculosis. The clinical efficacy of interferon-gamma has been studied and evaluated in clinical trials since the end of the last century. There was obtained evidence of the clinical efficacy of interferon-gamma as part of complex therapy. Recent experimental data make it possible to consider interferon-gamma as a promising therapeutic option for the treatment of multidrug-resistant tuberculosis as part of complex therapy worthy of further studies.
结核病是全球重大的健康问题之一。寻求改善结核病治疗效果和克服耐药性的方法在于了解感染过程发展的发病机制。干扰素系统,尤其是γ干扰素的作用,已被确定为结核病免疫反应的主要环节。自上世纪末以来,γ干扰素的临床疗效已在临床试验中得到研究和评估。有证据表明γ干扰素作为综合治疗的一部分具有临床疗效。最近的实验数据使人们有可能将γ干扰素视为作为综合治疗一部分治疗耐多药结核病的一种有前景的治疗选择,值得进一步研究。